PRKN and non-small cell lung carcinoma: In this study, we show that gefitinib, an inhibitor of epidermal growth factor receptor (EGFR) that is widely used for clinical therapy of non-small-cell lung cancer (NSCLC), strikingly enhances PINK1/Parkin-mediated mitophagy.